Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder the confirmation certificate received from the SEBI Registered Share Transfer Agent viz. Purva Sharegistry (India) Pvt. Ltd. for the quarter ended March 31st 2022. Kindly take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Yearly Compliance Certificate Under Regulation 7(3) Of Sebl Listing Regulations, 2015
In Compliance to Regulation 7(3) of SEBI Listing Regulations, 2015; we furnish hereunder the Certificate, duly signed by the Company Secretary of Fredun Pharmaceuticals Limited and by the Compliance Officer of 'Purva Sharegistry (India) Private Ltd.', designated Share Transfer Agent of the Company for the year ended March 31, 2022. Kindly take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JINKAL SHAHDesignation :- Company Secretary and Compliance Officer Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of The Board Meeting
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 08th April, 2022 at 11:00 am had considered and approved the following items of Business: 1. Appointment of Ms. Kala Agarwal, Practising Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for the Financial Year 2021-2022. The Meeting of the Board Commenced at 11:00 A.M. and concluded at 12:15 P.M. Kindly oblige and take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and 'Code of Conduct for Prevention of Insider Trading' of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), the trading window for dealing in securities of the Company will remain closed for designated persons and their immediate relatives with effect from 1st April, 2022 till 48 hours after the end of the Board Meeting wherein; the approval of Audited Financial Results for the quarter and financial year ended 31st March 2022, would be considered, approved and declared. The said information is being notified to all designated persons under the above Regulations. Kindly take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
In compliance to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we hereunder furnish a press release regarding receipt of approval for manufacturing Xenografts for various Dental and Orthopaedic surgical appliances from Central Drugs Standard Control Organisation (CDSCO), India. Kindly take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
In compliance to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015; we furnish hereunder a presentation giving a general overview of the Company's operations, its current capacity across the production line, a brief overview of its four business divisions, its strategic priorities and key highlights of Financial Year 2022. Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Quarter ended December 31st 2021; as approved by the Board in its Meeting held on Friday, January 28, 2022; published in Business Standard & Mumbai Lakshadeep newspaper(s) on January 29, 2022 Kindly take the same on your Records Fredun Pharmaceuticals Ltd - 539730 - Appointment of Company Secretary and Compliance Officer
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 28th January 2022 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended December 31st, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Appointment of Ms. Jinkal Shah as a Company Secretary and Compliance Officer of the Company with effect from 28th January, 2022. Fredun Pharmaceuticals Ltd - 539730 - Financials Results For The Quarter Ended 31St December, 2021
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Friday, 28th January 2022 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended December 31st, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; 2. Appointment of Ms. Jinkal Shah as a Company Secretary and Compliance Officer of the Company with effect from 28th January, 2022.